PRILOSEC (omeprazole magnesium) by R-Pharm US is compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the h/k atpase enzyme system at the secretory surface of the gastric parietal cell. First approved in 2008.
Drug data last refreshed 19h ago · AI intelligence enriched 2d ago
PRILOSEC (omeprazole magnesium) is an oral proton pump inhibitor that suppresses gastric acid secretion by blocking the H/K-ATPase enzyme system in gastric parietal cells. It treats gastroesophageal reflux disease (GERD), peptic ulcer disease, and related acid-related conditions. The delayed-release formulation allows targeted delivery to the small intestine for optimal acid suppression.
Mature product approaching loss of exclusivity with modest Part D volume; brand defense and transition planning will drive team focus.
compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H/K ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Esomeprazole Magnesium Dihydrate 40 mg Tablets Relative to Nexium 40 mg Tablets Under Fed Condition
Esomeprazole Magnesium Dihydrate 40 mg Tablets Relative to Nexium 40 mg Tablets Under Fasting Condition
Prilosec Bioequivalence Study in Healthy Volunteers
A Study to Compare Omeprazole Administered as Zegerid® Powder and as Prilosec® Capsule in Healthy Participants (P08050)(CL2010-12)
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
Worked on PRILOSEC at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on PRILOSEC offers limited growth trajectory but deep expertise in mature market dynamics, payer negotiation, and competitive defense. This is ideal for professionals seeking to master market access strategy and lifecycle management in a crowded therapeutic category.